🔗 Share this article

Given that America undertakes historic revisions to its immunization guidelines, an unexpected name has emerged somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by questioning coronavirus vaccines during the global health crisis and has concentrated on possible deaths after Covid immunization in her recent tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Immunization Schedule

Health officials had intended to unveil radical revisions to the pediatric immunization program recently, aligning the US with Denmark’s immunization schedule, it is understood – a substantial departure that would put the US out of step with a large portion of the global community with no evidence for improved outcomes. The planned update has been postponed until the next year.

Rather than the top vaccines chief, Høeg is set to address the audience at the meeting. She was recently named acting director of the FDA’s CDER, the fifth individual to run the office this year.

Consolidating Power at the FDA

The acting appointment could signify a tighter collaboration between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it points to a greater focus upon reevaluating long-standing vaccines at the FDA.

The new acting director has frequently advocated for discontinuing some pediatric vaccine recommendations in the US so as to align more in line with the Danish model, a country with universal health coverage and a population approximately the population of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccination policy – traditionally the purview of Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Questions Over Qualifications

The appointee has little discernible experience in pharmaceutical research, oversight or management, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a sizeable institution. She is not an expert in industry regulation.”

Previous commissioners of the center would “grasp legal statutes and the research of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she lacks the sort of resume that prior appointees who ran CBER have had.”

CDER has an vast workload at the FDA, Woodcock pointed out.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office approves a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and so forth, and every single one must be supervised,” Dr. Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial administrative element to the role, which supervises in excess of 5,000 employees. “It is a huge leadership role, if you execute it properly,” the former official added.

Official Statement and Controversial Programs

Regarding questions about Dr. Høeg's fitness for the role and whether this appointment signifies more teamwork among FDA leaders on immunizations, a representative responded that the “inquiries are based on inaccurate premises”.

“Her experience aligns with the duties of her position,” the spokesperson said, noting the months Dr. Høeg spent advising the agency head on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a contentious rapid medication authorization process that allegedly worried her predecessors. “How are these therapies being picked for this expedited pathway? Who makes the choices?” Howard asked. “There is a lot of confidentiality going on at the FDA right now.”

In general, he said, “the agency looks to be trending towards less stringent regulations of all drugs, with the exception of shots.”

Established Track Record on Immunizations

With vaccines, Dr. Høeg has a clearer, if troubling, history, Howard said. She released a study using non-validated public submissions to estimate the rate of myocarditis after COVID-19 immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccines are more dangerous than they are.

Among her “desired changes” for the new government encompassed changing rules for novel immunizations and ending “non-essential” immunizations, she stated after the election on a online show. At the agency, Dr. Høeg has according to sources floated the idea of barring young men from getting COVID-19 vaccinations.

“She’s an all-around ideologue who begins with her conclusions and reverse-engineers to retrofit the science in a highly disingenuous, dishonest fashion,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of fellow contrarians, {like|